The complaint follows a nearly three-year FTC investigation. Hims has rejected the allegations, stating the agency ignored evidence it provided and pledging vigorous defense. The specific scope of data sharing and the full extent of billing practices alleged remain subject to discovery.
Attorneys should monitor this case closely. It targets a major direct-to-consumer prescription brand on two heavily scrutinized issues—health-data privacy and subscription billing—and seeks injunctive relief, monetary damages, and civil penalties. The naming of major ad-tech platforms signals potential downstream regulatory pressure on data brokers and advertising networks handling health information. For companies in telehealth, DTC pharmaceuticals, or subscription services, the complaint provides a roadmap of FTC enforcement priorities around consumer disclosures and data-sharing practices.